Literature DB >> 18589060

A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia.

Theodore E Warkentin1, Michael Makris, Richard M Jay, John G Kelton.   

Abstract

BACKGROUND: Antibodies against the "self" protein, platelet factor 4 (PF4), bound to heparin-the cause of immune heparin-induced thrombocytopenia-are believed invariably to be triggered by preceding heparin therapy. We describe a novel syndrome, spontaneous heparin-induced thrombocytopenia, in which clinical and serologic features characteristic of this adverse drug reaction develop in patients despite the absence of preceding heparin therapy.
METHODS: Three patients met the study criteria (clinical and serologic features of heparin-induced thrombocytopenia without preceding heparin exposure), of whom 2 patients were identified among 225 patients (0.89%, 95% confidence interval, 0.11%-3.17%) with serologically confirmed heparin-induced thrombocytopenia recognized during an 18-year period at 1 hospital. The platelet serotonin-release assay was used to detect heparin-dependent immunoglobulin G-induced platelet activation, and 2 enzyme immunoassays were used to detect antibodies against PF4/heparin.
RESULTS: Two patients presented with thrombocytopenia and multiple arterial thrombosis, and 1 patient presented with anaphylactoid reactions after 2 subcutaneous injections of low-molecular-weight heparin. All 3 patients had high levels of platelet-activating anti-PF4/heparin antibodies of immunoglobulin G class at presentation despite the absence of previous heparin exposure. However, each patient did have a preceding infectious or inflammatory event; 1 patient had concomitant antiphospholipid antibodies.
CONCLUSION: Circumstances other than heparin use can trigger a spontaneous disorder that closely mimics heparin-induced thrombocytopenia, further supporting the autoimmune nature of this adverse drug reaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589060     DOI: 10.1016/j.amjmed.2008.03.012

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  45 in total

1.  Fondaparinux-associated heparin-induced thrombocytopenia.

Authors:  Micah Burch; Barry Cooper
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-01

2.  Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Authors:  Douglas B Cines; Serge V Yarovoi; Sergei V Zaitsev; Tatiana Lebedeva; Lubica Rauova; Mortimer Poncz; Gowthami M Arepally; Sanjay Khandelwal; Victoria Stepanova; Ann H Rux; Adam Cuker; Cecilia Guo; Linnette Mae Ocariza; Richard J Travers; Stephanie A Smith; Hugh Kim; James H Morrissey; Edward M Conway
Journal:  Blood Adv       Date:  2016-11-22

3.  Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia.

Authors:  Mehraboon Irani; Eric Siegal; Abhay Jella; Richard Aster; Anand Padmanabhan
Journal:  Transfusion       Date:  2018-12-17       Impact factor: 3.157

4.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

5.  Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.

Authors:  Matthew T Rondina; Amanda Walker; Robert C Pendleton
Journal:  Hosp Pract (1995)       Date:  2010-04

Review 6.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 7.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

8.  Accelerated arterial and venous clots in a young pregnant woman: a saga of thrombotic storm.

Authors:  Madan Raj Aryal; Madan Badal; Naresh Bhandari; Vijaya Raj Bhatt
Journal:  BMJ Case Rep       Date:  2013-05-27

9.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

10.  Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study.

Authors:  Robert L Levine; Georgene W Hergenroeder; John L Francis; Charles C Miller; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.